Product Images Clopidogrel Bisulfate

NuCare Pharmaceuticals is a manufacturer of Clopidogrel 75mg tablets packaged in a bottle of 90 tablets. The lot number is 000000 and the NDC number is 68071-4268-09. The manufacturer NDC is 47335-894-81 with an expiration date of 00-00. The label provides a warning to keep it away from children and store it at 59-86°F. Contact a doctor for any medical advice about side effects or report it to FDA at 1-800-FDA-1088.*

The text describes a figure labeled "Figure 8," which shows hazard ratios and confidence intervals for baseline subgroups in the CAPRIE Study. The quality of clopidogrel and aspirin is compared, and the figure includes data on stroke (Stk) and peripheral arterial disease (PAD) for each treatment. The hazard ratio and confidence intervals are shown over time (0607 to 080910111213). The text provides no other information.*

This is a figure depicting the exposure to Clopidogrel Active Metabolite after taking multiple doses of Clopidogrel 75mg alone or with Proton Pump Inhibitors (PPIs). The figure shows the effect of coadministered PPIs on the active metabolite AUC (area under the curve) with mean and 90% confidence interval. The PPIs included Dexlansoprazole 60mg, Lansoprazole 30mg, Pantoprazole 80mg, and Omeprazole 80mg. The change relative to clopidogrel administered alone is also displayed.*

This is a graph (Figure 2) presenting the results of the CURE Study on the incidence of cardiovascular death, myocardial infarction, and stroke. The study compared the placebo (taken with aspirin) to Clopidogrel (taken with aspirin). The cumulative event rate is shown as a percentage on the y-axis and the months of follow-up are shown on the x-axis. The data suggests that the incidence of cardiovascular death, myocardial infarction, and stroke was lower in the group taking Clopidogrel (plus aspirin) compared to the placebo (plus aspirin). Other standard therapies were also used as needed.*

This is a table showing patient baseline characteristics and on-study concomitant medications/interventions for the CURE study, including the hazard ratio for each subgroup. The table includes information on age, gender, race, history of cardiovascular disease, aspirin and other drug use, and whether patients were taking clopidogrel or placebo.*

The text describes a figure labeled as "Figure 4" that shows the cumulative event rates for death in the COMMIT study. The graph displays data for patients treated with a placebo and those treated with clopidogrel. The y-axis shows the percentage of patients who died before first discharge, and the x-axis displays the days since randomization. The graph indicates that the proportion of deaths was lower among patients treated with clopidogrel than with a placebo. All patients received aspirin as part of the treatment.*

This is a figure from the COMMIT study showing cumulative event rates for combined endpoint (re-infarction, stroke, or death) in patients who experienced death, reinfarction, or stroke before first discharge. The figure presents the event rates for two groups: Placebo (2310 events, 10.1%) and Clopidogrel (2121 events, 9.2%), showing a 9% proportional risk reduction (p=0.002) in favor of Clopidogrel. The x-axis shows the number of days since randomization (up to 28 days) and the y-axis shows the cumulative event rate. All patients in the study received aspirin.*

The text is a statistical table showing the effects of adding Clopidogrel to Aspirin for different subgroups in the COMMIT study, with data on gender, age, hours since onset, blood pressure, heart rate, and fibrinolytic agent intake. The table contains the number and percentage of patients receiving Clopidogrel and Placebo, and Odds Ratio with 95% confidence interval is shown.*